Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2020

View Archived Issues

Stromal cell subtypes identified in TNBC

From variants to treatments in neurology

New selective NKCC1 inhibitor for neurological conditions with impaired chloride ion homeostasis

LION/repRNA-CoV2S vaccine candidate shows efficacy in vivo

Phase III data presented for incobotulinumtoxin A in post-stroke upper-limb spasticity

Beijing Scitech-Mq Pharmaceuticals patents multitarget inhibitors

New phosphodiesterase PDE3A and PDE3B inhibitors disclosed by Bayer, The Broad Institute

Medshine Discovery discovers PD-L1 expression inhibitors

Jiangsu Hansoh Pharmaceutical, Shanghai Hansoh Biomedical identify agents targeting 5-HT2A/DRD3

Aeovian Pharmaceuticals identifies new mTORC1 inhibitors

Vivozon halts phase III study of opiranserin due to COVID-19 outbreak in the U.S.

Homozygous mutations in BTG4 are responsible for the phenotype of zygotic cleavage failure

FDA approves Enspryng for neuromyelitis optica spectrum disorder

Missense variants in the TRIP13 gene cause oocyte meiotic arrest resulting in female infertility

Discovery of autoantibody biomarkers for SLE diagnosis using a 2-phase proteome microarray strategy

Dosing initiates in phase IIa study of ASC-22 in patients with chronic hepatitis B

Starpharma and Chase Sun to develop novel DEP nanoparticle formulations

Specific miRNA-1 oxidation encodes cardiac hypertrophy

Kiadis announces K-NK-cell technology program for the development of COVID-19 therapy

Novavax initiates phase IIb efficacy trial of NVX-CoV2373 in South Africa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...